Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. executive Lance A. Berry reported a tax-related share sale. On this Form 4, the EVP, COO, CFO & Treasurer sold 5,178 shares of common stock at an average price of $38.0249 per share in connection with the vesting of restricted stock units.
The filing explains that the shares were sold solely to satisfy tax withholding obligations through a “sell to cover” arrangement and is described as a non-discretionary transaction rather than an elective open-market sale. After this transaction, Berry directly holds 176,269 shares of Artivion common stock.
ARTIVION, INC. Chief Commercial Officer John E. Davis reported an open-market sale of 2,784 shares of common stock. The shares were sold at an average price of $38.0249 per share in connection with the vesting of restricted stock units to cover tax withholding obligations.
After this sell-to-cover, Davis directly holds 206,522 shares of Artivion common stock. The filing states that this transaction was not discretionary and was executed solely to satisfy required tax withholding on equity compensation.
AORT reported a Form 144 notice regarding the proposed sale of 2,183 shares of Common stock tied to restricted stock vesting on 02/27/2026. The filing also discloses prior sales by Jean F. Holloway of 3,079 shares on 02/23/2026 and 1,668 shares on 02/24/2026.
The issuer filed a Form 144 related to the proposed sale of 14,911 common shares tied to restricted stock vesting dated 02/27/2026. The excerpt also lists recent sales by James Mackin: 30,921 shares on 12/02/2025 for $1,408,736.02, 30,921 shares on 12/03/2025 for $1,405,693.40, 20,962 shares on 02/23/2026 for $787,909.17, and 13,936 shares on 02/24/2026 for $497,416.25.
AORT submitted a Form 144 notice disclosing a proposed sale of 2,784 common shares with an aggregate value of $105,861.32. The filing lists the transaction type as Restricted Stock Vesting and shows the sale notice dated 03/02/2026.
The form also records recent dispositions by John E. Davis of 3,773 shares on 02/23/2026 and 2,075 shares on 02/24/2026, with aggregate amounts shown for each sale.
Amy D. Horton reported proposed sales of common stock under a Form 144. The filing lists a restricted stock vesting event of 641 shares on 02/27/2026 described as issuer compensation and multiple sales during the prior three months: 4,572 shares on 12/08/2025, 1,731 shares on 02/23/2026, and 830 shares on 02/24/2026.
The broker of record shown is Fidelity Brokerage Services LLC and the filing references a transaction date of 03/02/2026.
AORT Form 144: a notice of proposed and recent sales of Common stock. The filing lists a proposed sale tied to Restricted Stock Vesting on 02/27/2026 for 5,178 shares. It also reports prior sales by Lance Berry of 4,981 shares on 02/23/2026 for $187,223.34 and 4,485 shares on 02/24/2026 for $160,082.66.
AORT insider filings report proposed and completed transactions in common stock. The filing lists a restricted stock vesting of 1,513 shares on 02/27/2026 described as issuer compensation. It also reports past sales by Marshall S. Stanton of 2,423 shares for $91,074.51 on 02/23/2026 and 1,259 shares for $44,937.36 on 02/24/2026.
ARTIVION, INC. executive Amy Horton, VP and Chief Accounting Officer, reported both stock sales and a stock grant. On February 23, 2026, she sold 1,731 shares of common stock at $37.588 per share, and on February 24, 2026, she sold 830 shares at $35.693 per share.
According to the footnotes, both sales were automatic "sell to cover" transactions to pay tax withholding upon vesting of performance and restricted stock units, and did not represent discretionary trades. Horton also received a grant of 5,658 shares of restricted stock at no cost, which vest in three equal annual installments, and held 133,155 shares directly after these transactions.
Artivion, Inc. SVP Stanton Marshall S. reported two open-market sales of common stock that were executed solely to cover tax withholding on vesting equity awards. On February 23, 2026, he sold 2,423 shares at an average price of $37.588 per share. On February 24, 2026, he sold an additional 1,259 shares at an average price of $35.693 per share. The footnotes state these were "sell to cover" transactions to satisfy tax obligations and did not represent discretionary trading decisions. After the latest transaction, he directly owned 41,921 common shares.